{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T02:36:04Z","timestamp":1785638164539,"version":"3.56.0"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Danish Cardiovascular Academy","award":["PhD2021003-DCA"],"award-info":[{"award-number":["PhD2021003-DCA"]}]},{"DOI":"10.13039\/501100004836","name":"Danish Council for Independent Research","doi-asserted-by":"crossref","award":["DFF 9060-00046B"],"award-info":[{"award-number":["DFF 9060-00046B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004954","name":"Augustinus Fonden","doi-asserted-by":"publisher","award":["21-1561"],"award-info":[{"award-number":["21-1561"]}],"id":[{"id":"10.13039\/501100004954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pflugers Arch - Eur J Physiol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00424-025-03069-5","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T11:48:32Z","timestamp":1739879312000},"page":"773-786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Emerging roles of PCSK9 in kidney disease: lipid metabolism, megalin regulation and proteinuria"],"prefix":"10.1007","volume":"477","author":[{"given":"Sandra","family":"Hummelgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Kresse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Schou","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Glerup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Weyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"issue":"1","key":"3069_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1172\/JCI129937","volume":"130","author":"M Bedin","year":"2020","unstructured":"Bedin M et al (2020) Human C-terminal CUBN variants associate with chronic proteinuria and normal renal function. J Clin Invest 130(1):335\u2013344","journal-title":"J Clin Invest"},{"issue":"11","key":"3069_CR2","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1681\/ASN.2006040377","volume":"17","author":"M Abbate","year":"2006","unstructured":"Abbate M, Zoja C, Remuzzi G (2006) How does proteinuria cause progressive renal damage? J Am Soc Nephrol 17(11):2974\u20132984","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"3069_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M et al (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34(2):154\u2013156","journal-title":"Nat Genet"},{"issue":"1","key":"3069_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrneph.2017.155","volume":"14","author":"S Agrawal","year":"2018","unstructured":"Agrawal S et al (2018) Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 14(1):57\u201370","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"3069_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/ATVBAHA.124.321366","volume":"45","author":"N Amioka","year":"2025","unstructured":"Amioka N et al (2025) Renal proximal tubule cell-specific megalin deletion does not affect atherosclerosis but induces tubulointerstitial nephritis in mice fed a western diet. Arterioscler Thromb Vasc Biol 45(1):74\u201389","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"3069_CR6","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1681\/ASN.2010050492","volume":"21","author":"S Amsellem","year":"2010","unstructured":"Amsellem S et al (2010) Cubilin is essential for albumin reabsorption in the renal proximal tubule. J Am Soc Nephrol 21(11):1859\u20131867","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3069_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1083\/jcb.93.3.523","volume":"93","author":"RG Anderson","year":"1982","unstructured":"Anderson RG et al (1982) Surface distribution and recycling of the low density lipoprotein receptor as visualized with antireceptor antibodies. J Cell Biol 93(3):523\u2013531","journal-title":"J Cell Biol"},{"issue":"3","key":"3069_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0092-8674(77)90022-8","volume":"10","author":"RG Anderson","year":"1977","unstructured":"Anderson RG, Brown MS, Goldstein JL (1977) Role of the coated endocytic vesicle in the uptake of receptor-bound low density lipoprotein in human fibroblasts. Cell 10(3):351\u2013364","journal-title":"Cell"},{"issue":"6","key":"3069_CR9","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.kint.2020.07.027","volume":"98","author":"F Artunc","year":"2020","unstructured":"Artunc F (2020) Kidney-derived PCSK9-a new driver of hyperlipidemia in nephrotic syndrome? Kidney Int 98(6):1393\u20131395","journal-title":"Kidney Int"},{"issue":"1","key":"3069_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12882-017-0644-0","volume":"18","author":"Y Awanami","year":"2017","unstructured":"Awanami Y et al (2017) Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report. BMC Nephrol 18(1):221","journal-title":"BMC Nephrol"},{"issue":"9753","key":"3069_CR11","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753):1670\u20131681","journal-title":"Lancet"},{"issue":"4","key":"3069_CR12","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cell.2023.01.016","volume":"186","author":"A Beenken","year":"2023","unstructured":"Beenken A et al (2023) Structures of LRP2 reveal a molecular machine for endocytosis. Cell 186(4):821-836.e13","journal-title":"Cell"},{"issue":"47","key":"3069_CR13","doi-asserted-by":"publisher","first-page":"48865","DOI":"10.1074\/jbc.M409699200","volume":"279","author":"S Benjannet","year":"2004","unstructured":"Benjannet S et al (2004) NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 279(47):48865\u201348875","journal-title":"J Biol Chem"},{"issue":"1","key":"3069_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.atherosclerosis.2015.01.012","volume":"239","author":"JM Berger","year":"2015","unstructured":"Berger JM et al (2015) PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension. Atherosclerosis 239(1):252\u2013259","journal-title":"Atherosclerosis"},{"issue":"10225","key":"3069_CR15","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"B Bikbov","year":"2020","unstructured":"Bikbov B et al (2020) Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395(10225):709\u2013733","journal-title":"Lancet"},{"issue":"10","key":"3069_CR16","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1172\/JCI8862","volume":"105","author":"H Birn","year":"2000","unstructured":"Birn H et al (2000) Cubilin is an albumin binding protein important for renal tubular albumin reabsorption. J Clin Invest 105(10):1353\u20131361","journal-title":"J Clin Invest"},{"issue":"6","key":"3069_CR17","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.kint.2023.07.030","volume":"104","author":"H Birn","year":"2023","unstructured":"Birn H, Nielsen R, Weyer K (2023) Tubular albumin uptake: is there evidence for a quantitatively important, receptor-independent mechanism? Kidney Int 104(6):1069\u20131073","journal-title":"Kidney Int"},{"issue":"4746","key":"3069_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1126\/science.3513311","volume":"232","author":"MS Brown","year":"1986","unstructured":"Brown MS, Goldstein JL (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232(4746):34\u201347","journal-title":"Science"},{"issue":"3","key":"3069_CR19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/0092-8674(83)90052-1","volume":"32","author":"MS Brown","year":"1983","unstructured":"Brown MS, Anderson RG, Goldstein JL (1983) Recycling receptors: the round-trip itinerary of migrant membrane proteins. Cell 32(3):663\u2013667","journal-title":"Cell"},{"issue":"8","key":"3069_CR20","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.34067\/KID.0007022021","volume":"3","author":"JH Byun","year":"2022","unstructured":"Byun JH (2022) Inhibitory antibodies against PCSK9 reduce surface CD36 and mitigate diet-induced renal lipotoxicity. Kidney360 3(8):1394\u20131410","journal-title":"Kidney360"},{"issue":"23","key":"3069_CR21","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","volume":"73","author":"DM Charytan","year":"2019","unstructured":"Charytan DM et al (2019) Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J Am Coll Cardiol 73(23):2961\u20132970","journal-title":"J Am Coll Cardiol"},{"key":"3069_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40364-017-0111-x","volume":"5","author":"SC Chien","year":"2017","unstructured":"Chien SC et al (2017) Critical appraisal of the role of serum albumin in cardiovascular disease. Biomark Res 5:31","journal-title":"Biomark Res"},{"issue":"4","key":"3069_CR23","first-page":"223","volume":"27","author":"EI Christensen","year":"2012","unstructured":"Christensen EI et al (2012) Endocytic receptors in the renal proximal tubule. Physiology (Bethesda) 27(4):223\u2013236","journal-title":"Physiology (Bethesda)"},{"issue":"4","key":"3069_CR24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.kint.2020.11.015","volume":"99","author":"EI Christensen","year":"2021","unstructured":"Christensen EI et al (2021) A well-developed endolysosomal system reflects protein reabsorption in segment 1 and 2 of rat proximal tubules. Kidney Int 99(4):841\u2013853","journal-title":"Kidney Int"},{"issue":"4","key":"3069_CR25","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nrm778","volume":"3","author":"EI Christensen","year":"2002","unstructured":"Christensen EI, Birn H (2002) Megalin and cubilin: multifunctional endocytic receptors. Nat Rev Mol Cell Biol 3(4):256\u2013266","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"3069_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"J Cohen","year":"2005","unstructured":"Cohen J et al (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37(2):161\u2013165","journal-title":"Nat Genet"},{"issue":"12","key":"3069_CR27","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC et al (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354(12):1264\u20131272","journal-title":"N Engl J Med"},{"issue":"6133","key":"3069_CR28","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1126\/science.1239101","volume":"340","author":"JC Cohen","year":"2013","unstructured":"Cohen JC, Hobbs HH (2013) Simple genetics for a complex disease. Science 340(6133):689\u2013690","journal-title":"Science"},{"key":"3069_CR29","doi-asserted-by":"publisher","first-page":"1478697","DOI":"10.3389\/fmed.2024.1478697","volume":"11","author":"M Cortinovis","year":"2024","unstructured":"Cortinovis M, Perico N, Remuzzi G (2024) Tubulointerstitial injury in proteinuric chronic kidney diseases. Front Med (Lausanne) 11:1478697","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"3069_CR30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nsmb1235","volume":"14","author":"D Cunningham","year":"2007","unstructured":"Cunningham D et al (2007) Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 14(5):413\u2013419","journal-title":"Nat Struct Mol Biol"},{"key":"3069_CR31","doi-asserted-by":"crossref","unstructured":"de Sain-van der Velden MG et al (1998) Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int 53(4):994\u20131001","DOI":"10.1111\/j.1523-1755.1998.00831.x"},{"key":"3069_CR32","doi-asserted-by":"publisher","first-page":"6677012","DOI":"10.1155\/2021\/6677012","volume":"2021","author":"E Dounousi","year":"2021","unstructured":"Dounousi E et al (2021) Association between PCSK9 levels and markers of inflammation, oxidative stress, and endothelial dysfunction in a population of nondialysis chronic kidney disease patients. Oxid Med Cell Longev 2021:6677012","journal-title":"Oxid Med Cell Longev"},{"issue":"7","key":"3069_CR33","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1681\/ASN.0000000000000357","volume":"35","author":"A Faivre","year":"2024","unstructured":"Faivre A (2024) Spatiotemporal landscape of kidney tubular responses to glomerular proteinuria. J Am Soc Nephrol 35(7):854\u2013869","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"3069_CR34","doi-asserted-by":"publisher","first-page":"e23127","DOI":"10.1096\/fj.202300342RRR","volume":"37","author":"Z Feng","year":"2023","unstructured":"Feng Z et al (2023) PCSK9 causes inflammation and cGAS\/STING pathway activation in diabetic nephropathy. Faseb j 37(9):e23127","journal-title":"Faseb j"},{"issue":"32","key":"3069_CR35","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA et al (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 38(32):2459\u20132472","journal-title":"Eur Heart J"},{"issue":"28","key":"3069_CR36","doi-asserted-by":"publisher","first-page":"20502","DOI":"10.1074\/jbc.M701634200","volume":"282","author":"TS Fisher","year":"2007","unstructured":"Fisher TS et al (2007) Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem 282(28):20502\u201320512","journal-title":"J Biol Chem"},{"issue":"1","key":"3069_CR37","first-page":"19","volume":"85","author":"GW Go","year":"2012","unstructured":"Go GW, Mani A (2012) Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J Biol Med 85(1):19\u201328","journal-title":"Yale J Biol Med"},{"issue":"22","key":"3069_CR38","doi-asserted-by":"publisher","first-page":"e2318859121","DOI":"10.1073\/pnas.2318859121","volume":"121","author":"S Goto","year":"2024","unstructured":"Goto S et al (2024) Cryo-EM structures elucidate the multiligand receptor nature of megalin. Proc Natl Acad Sci U S A 121(22):e2318859121","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"3069_CR39","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1084\/jem.124.6.1123","volume":"124","author":"RC Graham Jr","year":"1966","unstructured":"Graham RC Jr, Karnovsky MJ (1966) Glomerular permeability: Ultrastructural cytochemical studies using peroxidases as protein tracers. J Exp Med 124(6):1123","journal-title":"J Exp Med"},{"issue":"1","key":"3069_CR40","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41467-017-00568-7","volume":"8","author":"C Gustafsen","year":"2017","unstructured":"Gustafsen C et al (2017) Heparan sulfate proteoglycans present PCSK9 to the LDL receptor. Nat Commun 8(1):503","journal-title":"Nat Commun"},{"issue":"1","key":"3069_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.115.020912","volume":"134","author":"ME Haas","year":"2016","unstructured":"Haas ME et al (2016) The role of proprotein convertase Subtilisin\/Kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation 134(1):61\u201372","journal-title":"Circulation"},{"issue":"37","key":"3069_CR42","doi-asserted-by":"publisher","first-page":"14604","DOI":"10.1073\/pnas.0703402104","volume":"104","author":"EN Hampton","year":"2007","unstructured":"Hampton EN et al (2007) The self-inhibited structure of full-length PCSK9 at 1.9 \u00c5 reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci 104(37):14604\u201314609","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"3069_CR43","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","volume":"193","author":"AJ Hooper","year":"2007","unstructured":"Hooper AJ et al (2007) The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 193(2):445\u2013448","journal-title":"Atherosclerosis"},{"key":"3069_CR44","doi-asserted-by":"publisher","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","volume":"50","author":"JD Horton","year":"2009","unstructured":"Horton JD, Cohen JC, Hobbs HH (2009) PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 50:S172\u2013S177","journal-title":"J Lipid Res"},{"key":"3069_CR45","unstructured":"Hummelgaard S (2024) Investigation of PCSK9 as a new target to mitigate proteinuria in kidney disease, in Department of Biomedicin. Aarhus University: Royal Danish Library, p 205"},{"key":"3069_CR46","doi-asserted-by":"publisher","first-page":"108480","DOI":"10.1016\/j.pharmthera.2023.108480","volume":"249","author":"S Hummelgaard","year":"2023","unstructured":"Hummelgaard S et al (2023) Targeting PCSK9 to tackle cardiovascular disease. Pharmacol Ther 249:108480","journal-title":"Pharmacol Ther"},{"issue":"1","key":"3069_CR47","doi-asserted-by":"publisher","first-page":"F48","DOI":"10.1152\/ajprenal.00065.2024","volume":"328","author":"S Hummelgaard","year":"2025","unstructured":"Hummelgaard S et al (2025) Lack of renoprotective effects by long-term PCSK9 and SGLT2 inhibition using alirocumab and empagliflozin in obese ZSF1 rats. Am J Physiol-Renal Physiol 328(1):F48\u2013F67","journal-title":"Am J Physiol-Renal Physiol"},{"issue":"3\u20134","key":"3069_CR48","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000526369","volume":"147","author":"S Hummelgaard","year":"2023","unstructured":"Hummelgaard S, Weyer K (2023) Megalin-mediated endocytosis in the kidney proximal tubule: relevance to regulation of the renal renin-angiotensin system. Nephron 147(3\u20134):244\u2013249","journal-title":"Nephron"},{"issue":"4","key":"3069_CR49","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1161\/01.ATV.20.4.1089","volume":"20","author":"SC Hunt","year":"2000","unstructured":"Hunt SC et al (2000) Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred. Arterioscler Thromb Vasc Biol 20(4):1089\u20131093","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"3069_CR50","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski J et al (2021) Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation 143(11):1157\u20131172","journal-title":"Circulation"},{"issue":"1","key":"3069_CR51","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ekir.2020.09.046","volume":"6","author":"E Jatem","year":"2021","unstructured":"Jatem E et al (2021) Efficacy and safety of PCSK9 inhibitors in hypercholesterolemia associated with refractory nephrotic syndrome. Kidney Int Rep 6(1):101\u2013109","journal-title":"Kidney Int Rep"},{"key":"3069_CR52","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1146\/annurev.biochem.74.082803.133354","volume":"74","author":"H Jeon","year":"2005","unstructured":"Jeon H, Blacklow SC (2005) Structure and physiologic function of the low-density lipoprotein receptor. Annu Rev Biochem 74:535\u2013562","journal-title":"Annu Rev Biochem"},{"issue":"4","key":"3069_CR53","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1053\/j.ajkd.2013.10.042","volume":"63","author":"K Jin","year":"2014","unstructured":"Jin K et al (2014) Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis 63(4):584\u2013589","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"3069_CR54","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/ng2063","volume":"39","author":"S Kantarci","year":"2007","unstructured":"Kantarci S et al (2007) Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes. Nat Genet 39(8):957\u2013959","journal-title":"Nat Genet"},{"issue":"16","key":"3069_CR55","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s40265-023-01952-y","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ (2023) Tafolecimab: First Approval. Drugs 83(16):1545\u20131549","journal-title":"Drugs"},{"issue":"6","key":"3069_CR56","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2215\/CJN.01230122","volume":"17","author":"A Kheirkhah","year":"2022","unstructured":"Kheirkhah A et al (2022) PCSK9 and cardiovascular disease in individuals with moderately decreased kidney function. Clin J Am Soc Nephrol 17(6):809\u2013818","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"3069_CR57","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000365935","volume":"40","author":"M Konarzewski","year":"2014","unstructured":"Konarzewski M et al (2014) Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy. Am J Nephrol 40(2):157\u2013163","journal-title":"Am J Nephrol"},{"issue":"1","key":"3069_CR58","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP (2022) Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl 12(1):7\u201311","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"3069_CR59","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1038\/s41598-023-31454-6","volume":"13","author":"K Kulkarni","year":"2023","unstructured":"Kulkarni K et al (2023) Angiotensin II type 2 receptor activation preserves megalin in the kidney and prevents proteinuria in high salt diet fed rats. Sci Rep 13(1):4277","journal-title":"Sci Rep"},{"issue":"2","key":"3069_CR60","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1681\/ASN.0000000572","volume":"36","author":"K Kulkarni","year":"2024","unstructured":"Kulkarni K, Hussain T (2024) Megalin: A Sidekick or Nemesis of the Kidney? J Am Soc Nephrol 36(2):293\u2013300","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"3069_CR61","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.atherosclerosis.2012.11.009","volume":"226","author":"AJ Kwakernaak","year":"2013","unstructured":"Kwakernaak AJ et al (2013) Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment. Atherosclerosis 226(2):459\u2013465","journal-title":"Atherosclerosis"},{"issue":"4","key":"3069_CR62","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/S0002-9440(10)65238-8","volume":"155","author":"JR Leheste","year":"1999","unstructured":"Leheste JR et al (1999) Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol 155(4):1361\u20131370","journal-title":"Am J Pathol"},{"issue":"9602","key":"3069_CR63","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","volume":"370","author":"S Lewington","year":"2007","unstructured":"Lewington S et al (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370(9602):1829\u20131839","journal-title":"Lancet"},{"issue":"1","key":"3069_CR64","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","volume":"5","author":"P Libby","year":"2019","unstructured":"Libby P et al (2019) Atherosclerosis. Nat Rev Dis Primers 5(1):56","journal-title":"Nat Rev Dis Primers"},{"issue":"29","key":"3069_CR65","doi-asserted-by":"publisher","first-page":"18018","DOI":"10.1074\/jbc.M115.662064","volume":"290","author":"D Liu","year":"2015","unstructured":"Liu D et al (2015) Megalin\/Cubulin-Lysosome-mediated Albumin Reabsorption Is Involved in the Tubular Cell Activation of NLRP3 Inflammasome and Tubulointerstitial Inflammation. J Biol Chem 290(29):18018\u201318028","journal-title":"J Biol Chem"},{"issue":"3","key":"3069_CR66","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/ndt\/gft439","volume":"29","author":"S Liu","year":"2014","unstructured":"Liu S, Vaziri ND (2014) Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome. Nephrol Dial Transplant 29(3):538\u2013543","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"3069_CR67","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/embor.2011.205","volume":"12","author":"P Lo Surdo","year":"2011","unstructured":"Lo Surdo P et al (2011) Mechanistic implications for LDL receptor degradation from the PCSK9\/LDLR structure at neutral pH. EMBO Rep 12(12):1300\u20131305","journal-title":"EMBO Rep"},{"issue":"4","key":"3069_CR68","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41580-019-0190-7","volume":"21","author":"J Luo","year":"2020","unstructured":"Luo J, Yang H, Song BL (2020) Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol 21(4):225\u2013245","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3069_CR69","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.atherosclerosis.2022.01.015","volume":"346","author":"MG Lupo","year":"2022","unstructured":"Lupo MG et al (2022) PCSK9 promotes arterial medial calcification. Atherosclerosis 346:86\u201397","journal-title":"Atherosclerosis"},{"issue":"1","key":"3069_CR70","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F et al (2020) 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111\u2013188","journal-title":"Eur Heart J"},{"issue":"2","key":"3069_CR71","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jacl.2017.12.018","volume":"12","author":"L Masana","year":"2018","unstructured":"Masana L et al (2018) Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis. J Clin Lipidol 12(2):292-299.e3","journal-title":"J Clin Lipidol"},{"issue":"10","key":"3069_CR72","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1681\/ASN.2020030263","volume":"32","author":"K Matsushita","year":"2021","unstructured":"Matsushita K et al (2021) Cilastatin Ameliorates Rhabdomyolysis-induced AKI in Mice. J Am Soc Nephrol 32(10):2579\u20132594","journal-title":"J Am Soc Nephrol"},{"issue":"18","key":"3069_CR73","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1073\/pnas.0402133101","volume":"101","author":"KN Maxwell","year":"2004","unstructured":"Maxwell KN, Breslow JL (2004) Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 101(18):7100\u20137105","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"3069_CR74","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","volume":"59","author":"JM McKenney","year":"2012","unstructured":"McKenney JM et al (2012) Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 59(25):2344\u20132353","journal-title":"J Am Coll Cardiol"},{"key":"3069_CR75","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/IJNRD.S101808","volume":"10","author":"I Mikolasevic","year":"2017","unstructured":"Mikolasevic I et al (2017) Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis 10:35\u201345","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"6","key":"3069_CR76","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.kint.2020.06.045","volume":"98","author":"E Molina-Jijon","year":"2020","unstructured":"Molina-Jijon E et al (2020) Secretion of the epithelial sodium channel chaperone PCSK9 from the cortical collecting duct links sodium retention with hypercholesterolemia in nephrotic syndrome. Kidney Int 98(6):1449\u20131460","journal-title":"Kidney Int"},{"issue":"10S","key":"3069_CR77","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1681\/ASN.202455z2anhe","volume":"35","author":"E Molina-Jijon","year":"2024","unstructured":"Molina-Jijon E et al (2024) Differential expression of renal and hepatic PCSK9 during development of hypercholesterolemia in the passive heymann nephritis rat model of nephrotic syndrome: FR-PO804. J Am Soc Nephrol 35(10S):10\u20131681. https:\/\/doi.org\/10.1681\/ASN.202455z2anhe","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3069_CR78","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1152\/physrev.00014.2021","volume":"102","author":"BA Molitoris","year":"2022","unstructured":"Molitoris BA et al (2022) Albumin uptake and processing by the proximal tubule: physiological, pathological, and therapeutic implications. Physiol Rev 102(4):1625\u20131667","journal-title":"Physiol Rev"},{"issue":"6","key":"3069_CR79","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.kint.2023.05.028","volume":"104","author":"BA Molitoris","year":"2023","unstructured":"Molitoris BA, Dunn KW, Sandoval RM (2023) Proximal tubule role in albumin homeostasis: controversy, species differences, and the contributions of intravital microscopy. Kidney Int 104(6):1065\u20131069","journal-title":"Kidney Int"},{"issue":"9","key":"3069_CR80","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nrneph.2016.111","volume":"12","author":"AW Morris","year":"2016","unstructured":"Morris AW (2016) Nephrotic syndrome: PCSK9: a target for hypercholesterolaemia in nephrotic syndrome. Nat Rev Nephrol 12(9):510","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"3069_CR81","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/ki.2008.405","volume":"74","author":"Y Motoyoshi","year":"2008","unstructured":"Motoyoshi Y et al (2008) Megalin contributes to the early injury of proximal tubule cells during nonselective proteinuria. Kidney Int 74(10):1262\u20131269","journal-title":"Kidney Int"},{"issue":"11","key":"3069_CR82","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3390\/metabo11110760","volume":"11","author":"P Mu\u00f1oz Ramos","year":"2021","unstructured":"Mu\u00f1oz Ramos P et al (2021) Proteinuria-lowering effects of proprotein convertase Subtilisin\/Kexin type 9 inhibitors in chronic kidney disease patients: a real-world multicentric study. Metabolites 11(11):760","journal-title":"Metabolites"},{"issue":"1","key":"3069_CR83","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMra1112570","volume":"366","author":"EG Nabel","year":"2012","unstructured":"Nabel EG, Braunwald E (2012) A tale of coronary artery disease and myocardial infarction. N Engl J Med 366(1):54\u201363","journal-title":"N Engl J Med"},{"issue":"5","key":"3069_CR84","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/ki.2013.218","volume":"84","author":"R Nielsen","year":"2013","unstructured":"Nielsen R et al (2013) Increased lysosomal proteolysis counteracts protein accumulation in the proximal tubule during focal segmental glomerulosclerosis. Kidney Int 84(5):902\u2013910","journal-title":"Kidney Int"},{"issue":"1","key":"3069_CR85","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.kint.2015.11.007","volume":"89","author":"R Nielsen","year":"2016","unstructured":"Nielsen R, Christensen EI, Birn H (2016) Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease. Kidney Int 89(1):58\u201367","journal-title":"Kidney Int"},{"issue":"37","key":"3069_CR86","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.2174\/1381612820666140212194926","volume":"20","author":"S Palit","year":"2014","unstructured":"Palit S, Kendrick J (2014) Vascular calcification in chronic kidney disease: role of disordered mineral metabolism. Curr Pharm Des 20(37):5829\u20135833","journal-title":"Curr Pharm Des"},{"issue":"4","key":"3069_CR87","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","volume":"157","author":"SC Palmer","year":"2012","unstructured":"Palmer SC et al (2012) Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 157(4):263\u2013275","journal-title":"Ann Intern Med"},{"issue":"5","key":"3069_CR88","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.str.2007.04.004","volume":"15","author":"DE Piper","year":"2007","unstructured":"Piper DE et al (2007) The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure 15(5):545\u2013552","journal-title":"Structure"},{"issue":"8","key":"3069_CR89","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.34067\/KID.0003272022","volume":"3","author":"J Pressly","year":"2022","unstructured":"Pressly J, Fornoni A (2022) The many lives of PCSK9: therapeutic implications. Kidney360 3(8):1296\u20131298","journal-title":"Kidney360"},{"issue":"16","key":"3069_CR90","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ et al (2020) Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med 382(16):1520\u20131530","journal-title":"N Engl J Med"},{"issue":"20","key":"3069_CR91","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJM199811123392007","volume":"339","author":"G Remuzzi","year":"1998","unstructured":"Remuzzi G, Bertani T (1998) Pathophysiology of progressive nephropathies. N Engl J Med 339(20):1448\u20131456","journal-title":"N Engl J Med"},{"issue":"5","key":"3069_CR92","doi-asserted-by":"publisher","first-page":"F1284","DOI":"10.1152\/ajprenal.00030.2020","volume":"318","author":"Q Ren","year":"2020","unstructured":"Ren Q et al (2020) Distinct functions of megalin and cubilin receptors in recovery of normal and nephrotic levels of filtered albumin. Am J Physiol Renal Physiol 318(5):F1284-f1294","journal-title":"Am J Physiol Renal Physiol"},{"issue":"16","key":"3069_CR93","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG et al (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1489\u20131499","journal-title":"N Engl J Med"},{"issue":"1","key":"3069_CR94","doi-asserted-by":"publisher","first-page":"e0146920","DOI":"10.1371\/journal.pone.0146920","volume":"11","author":"KS Rogacev","year":"2016","unstructured":"Rogacev KS et al (2016) PCSK9 plasma concentrations are independent of GFR and do not predict cardiovascular events in patients with decreased GFR. PLoS ONE 11(1):e0146920","journal-title":"PLoS ONE"},{"issue":"16","key":"3069_CR95","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS et al (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1500\u20131509","journal-title":"N Engl J Med"},{"issue":"18","key":"3069_CR96","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376(18):1713\u20131722","journal-title":"N Engl J Med"},{"issue":"7","key":"3069_CR97","doi-asserted-by":"publisher","first-page":"a004952","DOI":"10.1101\/cshperspect.a004952","volume":"3","author":"S Sarrazin","year":"2011","unstructured":"Sarrazin S, Lamanna WC, Esko JD (2011) Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol 3(7):a004952","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"3069_CR98","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1194\/jlr.M074427","volume":"58","author":"D Scerbo","year":"2017","unstructured":"Scerbo D et al (2017) Kidney triglyceride accumulation in the fasted mouse is dependent upon serum free fatty acids. J Lipid Res 58(6):1132\u20131142","journal-title":"J Lipid Res"},{"issue":"8","key":"3069_CR99","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1093\/ndt\/gfz122","volume":"34","author":"D Schmit","year":"2019","unstructured":"Schmit D, Fliser D, Speer T (2019) Proprotein convertase subtilisin\/kexin type 9 in kidney disease. Nephrol Dial Transplant 34(8):1266\u20131271","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"3069_CR100","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1083\/jcb.201410017","volume":"209","author":"RP Scott","year":"2015","unstructured":"Scott RP, Quaggin SE (2015) Review series: The cell biology of renal filtration. J Cell Biol 209(2):199\u2013210","journal-title":"J Cell Biol"},{"issue":"5","key":"3069_CR101","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrd3699","volume":"11","author":"NG Seidah","year":"2012","unstructured":"Seidah NG, Prat A (2012) The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 11(5):367\u2013383","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"3069_CR102","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","volume":"122","author":"MD Shapiro","year":"2018","unstructured":"Shapiro MD, Tavori H, Fazio S (2018) PCSK9: From basic science discoveries to clinical trials. Circ Res 122(10):1420\u20131438","journal-title":"Circ Res"},{"issue":"23","key":"3069_CR103","doi-asserted-by":"publisher","first-page":"19266","DOI":"10.1074\/jbc.M112.363382","volume":"287","author":"V Sharotri","year":"2012","unstructured":"Sharotri V et al (2012) Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin\/kexin type 9 (PCSK9)*. J Biol Chem 287(23):19266\u201319274","journal-title":"J Biol Chem"},{"issue":"1","key":"3069_CR104","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/0886022X.2020.1756846","volume":"42","author":"H Shen","year":"2020","unstructured":"Shen H et al (2020) Correlation between plasma proprotein convertase subtilisin\/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome. Ren Fail 42(1):405\u2013412","journal-title":"Ren Fail"},{"key":"3069_CR105","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.cellsig.2018.12.001","volume":"55","author":"P Shrestha","year":"2019","unstructured":"Shrestha P et al (2019) Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia. Cell Signal 55:53\u201364","journal-title":"Cell Signal"},{"issue":"6","key":"3069_CR106","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.kint.2021.01.023","volume":"99","author":"P Shrestha","year":"2021","unstructured":"Shrestha P et al (2021) Proteinuria converts hepatic heparan sulfate to an effective proprotein convertase subtilisin kexin type 9 enzyme binding partner. Kidney Int 99(6):1369\u20131381","journal-title":"Kidney Int"},{"issue":"6","key":"3069_CR107","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1681\/ASN.2020091376","volume":"32","author":"P Shrestha","year":"2021","unstructured":"Shrestha P et al (2021) Hypercholesterolemia in progressive renal failure is associated with changes in hepatic heparan sulfate - PCSK9 interaction. J Am Soc Nephrol 32(6):1371\u20131388","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3069_CR108","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.kint.2023.06.024","volume":"104","author":"CK Skeby","year":"2023","unstructured":"Skeby CK et al (2023) Proprotein convertase subtilisin\/kexin type 9 targets megalin in the kidney proximal tubule and aggravates proteinuria in nephrotic syndrome. Kidney Int 104(4):754\u2013768","journal-title":"Kidney Int"},{"issue":"9836","key":"3069_CR109","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"EA Stein","year":"2012","unstructured":"Stein EA et al (2012) Effect of a monoclonal antibody to PCSK9, REGN727\/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 380(9836):29\u201336","journal-title":"Lancet"},{"issue":"12","key":"3069_CR110","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","volume":"366","author":"EA Stein","year":"2012","unstructured":"Stein EA et al (2012) Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 366(12):1108\u20131118","journal-title":"N Engl J Med"},{"issue":"1","key":"3069_CR111","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41574-018-0110-5","volume":"15","author":"RM Stoekenbroek","year":"2018","unstructured":"Stoekenbroek RM et al (2018) Inhibiting PCSK9 - biology beyond LDL control. Nat Rev Endocrinol 15(1):52\u201362","journal-title":"Nat Rev Endocrinol"},{"issue":"1\u20132","key":"3069_CR112","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11010-015-2590-0","volume":"411","author":"E Sucajtys-Szulc","year":"2016","unstructured":"Sucajtys-Szulc E et al (2016) Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure. Mol Cell Biochem 411(1\u20132):281\u2013287","journal-title":"Mol Cell Biochem"},{"issue":"4701","key":"3069_CR113","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1126\/science.2988123","volume":"228","author":"TC S\u00fcdhof","year":"1985","unstructured":"S\u00fcdhof TC et al (1985) The LDL receptor gene: a mosaic of exons shared with different proteins. Science 228(4701):815\u2013822","journal-title":"Science"},{"issue":"6","key":"3069_CR114","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/protein\/12.6.439","volume":"12","author":"S Sugio","year":"1999","unstructured":"Sugio S et al (1999) Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng 12(6):439\u201346","journal-title":"Protein Eng"},{"issue":"9","key":"3069_CR115","doi-asserted-by":"publisher","first-page":"100199","DOI":"10.1016\/j.labinv.2023.100199","volume":"103","author":"T Suzuki","year":"2023","unstructured":"Suzuki T et al (2023) Effect of proprotein convertase subtilisin\/kexin type 9 inhibition on podocytes in mouse nephrotic syndrome. Lab Invest 103(9):100199","journal-title":"Lab Invest"},{"issue":"6","key":"3069_CR116","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1681\/ASN.2006111266","volume":"18","author":"F Theilig","year":"2007","unstructured":"Theilig F et al (2007) Abrogation of protein uptake through megalin-deficient proximal tubules does not safeguard against tubulointerstitial injury. J Am Soc Nephrol 18(6):1824\u20131834","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"3069_CR117","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","volume":"93","author":"PP Toth","year":"2018","unstructured":"Toth PP et al (2018) Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int 93(6):1397\u20131408","journal-title":"Kidney Int"},{"key":"3069_CR118","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2174\/1874192401105010041","volume":"5","author":"V Tsimihodimos","year":"2011","unstructured":"Tsimihodimos V, Mitrogianni Z, Elisaf M (2011) Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J 5:41\u201348","journal-title":"Open Cardiovasc Med J"},{"key":"3069_CR119","unstructured":"University of Oxford, T.T.S.G. and Novartis Pharmaceuticals (2026) A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease"},{"issue":"3","key":"3069_CR120","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/MOL.0000000000000411","volume":"28","author":"B van de Sluis","year":"2017","unstructured":"van de Sluis B, Wijers M, Herz J (2017) News on the molecular regulation and function of hepatic low-density lipoprotein receptor and LDLR-related protein 1. Curr Opin Lipidol 28(3):241\u2013247","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"3069_CR121","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1086\/302370","volume":"64","author":"M Varret","year":"1999","unstructured":"Varret M et al (1999) A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am J Human Gen 64(5):1378\u20131387","journal-title":"Am J Human Gen"},{"issue":"1","key":"3069_CR122","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","volume":"90","author":"ND Vaziri","year":"2016","unstructured":"Vaziri ND (2016) Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int 90(1):41\u201352","journal-title":"Kidney Int"},{"issue":"3","key":"3069_CR123","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/ki.1996.388","volume":"50","author":"ND Vaziri","year":"1996","unstructured":"Vaziri ND, Liang KH (1996) Down-regulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 50(3):887\u2013893","journal-title":"Kidney Int"},{"issue":"5","key":"3069_CR124","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1046\/j.1523-1755.2003.00911.x","volume":"63","author":"ND Vaziri","year":"2003","unstructured":"Vaziri ND, Sato T, Liang K (2003) Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. Kidney Int 63(5):1756\u20131763","journal-title":"Kidney Int"},{"issue":"9","key":"3069_CR125","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1194\/jlr.M028563","volume":"53","author":"Y Wang","year":"2012","unstructured":"Wang Y et al (2012) Molecular characterization of proprotein convertase subtilisin\/kexin type 9-mediated degradation of the LDLR. J Lipid Res 53(9):1932\u20131943","journal-title":"J Lipid Res"},{"issue":"10","key":"3069_CR126","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.1525-1497.2004.40049.x","volume":"19","author":"DE Weiner","year":"2004","unstructured":"Weiner DE, Sarnak MJ (2004) Managing dyslipidemia in chronic kidney disease. J Gen Intern Med 19(10):1045\u20131052","journal-title":"J Gen Intern Med"},{"issue":"11","key":"3069_CR127","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1093\/ndt\/gfr525","volume":"26","author":"K Weyer","year":"2011","unstructured":"Weyer K et al (2011) Mouse model of proximal tubule endocytic dysfunction. Nephrol Dial Transplant 26(11):3446\u20133451","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"3069_CR128","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.kint.2017.07.024","volume":"93","author":"K Weyer","year":"2018","unstructured":"Weyer K et al (2018) Abolishment of proximal tubule albumin endocytosis does not affect plasma albumin during nephrotic syndrome in mice. Kidney Int 93(2):335\u2013342","journal-title":"Kidney Int"},{"issue":"1","key":"3069_CR129","doi-asserted-by":"publisher","first-page":"e014358","DOI":"10.1161\/JAHA.119.014358","volume":"9","author":"D Wu","year":"2020","unstructured":"Wu D et al (2020) Vaccine against PCSK9 improved renal fibrosis by regulating fatty acid \u03b2-oxidation. J Am Heart Assoc 9(1):e014358","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"3069_CR130","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1007\/s00125-024-06191-8","volume":"67","author":"M Wu","year":"2024","unstructured":"Wu M et al (2024) The role of PCSK9 in glomerular lipid accumulation and renal injury in diabetic kidney disease. Diabetologia 67(9):1980\u20131997","journal-title":"Diabetologia"},{"issue":"4","key":"3069_CR131","doi-asserted-by":"publisher","first-page":"zqae026","DOI":"10.1093\/function\/zqae026","volume":"5","author":"EB Youm","year":"2024","unstructured":"Youm EB et al (2024) Megalin Knockout reduces SGLT2 expression and sensitizes to western diet-induced kidney injury. Function 5(4):zqae026","journal-title":"Function"},{"issue":"2","key":"3069_CR132","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/hep.22354","volume":"48","author":"A Zaid","year":"2008","unstructured":"Zaid A et al (2008) Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 48(2):646\u2013654","journal-title":"Hepatology"},{"issue":"25","key":"3069_CR133","doi-asserted-by":"publisher","first-page":"18602","DOI":"10.1074\/jbc.M702027200","volume":"282","author":"DW Zhang","year":"2007","unstructured":"Zhang DW et al (2007) Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 282(25):18602\u201318612","journal-title":"J Biol Chem"},{"issue":"35","key":"3069_CR134","doi-asserted-by":"publisher","first-page":"13045","DOI":"10.1073\/pnas.0806312105","volume":"105","author":"DW Zhang","year":"2008","unstructured":"Zhang DW et al (2008) Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci U S A 105(35):13045\u201313050","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"3069_CR135","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1086\/507488","volume":"79","author":"Z Zhao","year":"2006","unstructured":"Zhao Z et al (2006) Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 79(3):514\u2013523","journal-title":"Am J Hum Genet"}],"container-title":["Pfl\u00fcgers Archiv - European Journal of Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00424-025-03069-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00424-025-03069-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00424-025-03069-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:53:05Z","timestamp":1747734785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00424-025-03069-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":135,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3069"],"URL":"https:\/\/doi.org\/10.1007\/s00424-025-03069-5","relation":{},"ISSN":["0031-6768","1432-2013"],"issn-type":[{"value":"0031-6768","type":"print"},{"value":"1432-2013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SH and SG have significant financial interest in companies involved in the development of PCSK9 inhibitors. The remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}